JP2011514349A5 - - Google Patents

Download PDF

Info

Publication number
JP2011514349A5
JP2011514349A5 JP2010549670A JP2010549670A JP2011514349A5 JP 2011514349 A5 JP2011514349 A5 JP 2011514349A5 JP 2010549670 A JP2010549670 A JP 2010549670A JP 2010549670 A JP2010549670 A JP 2010549670A JP 2011514349 A5 JP2011514349 A5 JP 2011514349A5
Authority
JP
Japan
Prior art keywords
fulvestrant
poloxamer
formulation
polyethylene glycol
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010549670A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011514349A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/001437 external-priority patent/WO2009111057A2/en
Publication of JP2011514349A publication Critical patent/JP2011514349A/ja
Publication of JP2011514349A5 publication Critical patent/JP2011514349A5/ja
Pending legal-status Critical Current

Links

JP2010549670A 2008-03-07 2009-03-05 フルベストラント配合物 Pending JP2011514349A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6856008P 2008-03-07 2008-03-07
PCT/US2009/001437 WO2009111057A2 (en) 2008-03-07 2009-03-05 Fulvestrant formulations

Publications (2)

Publication Number Publication Date
JP2011514349A JP2011514349A (ja) 2011-05-06
JP2011514349A5 true JP2011514349A5 (enExample) 2012-04-19

Family

ID=41054291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010549670A Pending JP2011514349A (ja) 2008-03-07 2009-03-05 フルベストラント配合物

Country Status (8)

Country Link
US (7) US9180088B2 (enExample)
EP (1) EP2249839A4 (enExample)
JP (1) JP2011514349A (enExample)
KR (1) KR20100121505A (enExample)
CN (1) CN102014925B (enExample)
CA (1) CA2716576A1 (enExample)
WO (1) WO2009111057A2 (enExample)
ZA (1) ZA201006315B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101677987A (zh) * 2007-06-22 2010-03-24 赛多斯有限责任公司 不含吐温80的多西他赛的增溶制剂
JP2011514349A (ja) 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
JP4929423B2 (ja) 2010-07-22 2012-05-09 日本碍子株式会社 成形体、及び、成形体の製造方法
CA2836831C (en) 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600065B (zh) * 2012-03-31 2014-08-13 莱普德制药有限公司 一种氟维司群或其衍生物油性制剂及其制备方法
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
CA2869377C (en) * 2012-04-09 2022-11-08 Scidose, Llc Fulvestrant formulations
US20160060288A1 (en) * 2013-04-18 2016-03-03 Xi'anlibang Pharmaceutical Technology Co., Ltd. Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
HUP1300646A2 (en) * 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
CN109152785B (zh) 2016-05-31 2021-02-09 富士胶片株式会社 医药组合物
CN107789320B (zh) * 2016-08-31 2021-06-22 鲁南制药集团股份有限公司 一种氟维司群缓释注射液及其制备工艺
CA3032912A1 (en) * 2017-05-23 2018-11-29 Kashiv Biosciences, Llc High-concentration fulvestrant compositions
BR112020009141A2 (pt) * 2017-11-08 2020-10-27 Eagle Pharmaceuticals, Inc. método para tratar câncer de mama num indivíduo
KR20220079472A (ko) * 2020-12-04 2022-06-13 주식회사 삼양홀딩스 풀베스트란트의 서방형 약학 조성물 및 그 제조 방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2087721B (en) * 1980-11-20 1984-01-25 Beecham Group Ltd Injectable antibiotic formulations stabilised with glycofurol
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3406497A1 (de) 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
US20060264357A1 (en) 1997-04-22 2006-11-23 Zikria Bashir A Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
DK0999838T3 (da) 1997-07-29 2002-07-08 Upjohn Co Selv-emulgerende formulering for lipofile forbindelser
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
KR20020013174A (ko) 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
EP1345589B1 (en) 2000-11-29 2007-06-27 Lyotropic Therapeutics, Inc. Solvent systems for pharmaceutical agents
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1258243A1 (en) 2001-05-16 2002-11-20 N.V. Nutricia Lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy
GB0116620D0 (en) 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
AU2004265238A1 (en) 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin D compounds in combination with other treatments
CA2530407A1 (en) 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
US20050090551A1 (en) 2003-10-27 2005-04-28 Board Of Trustees Of Southern Illinois University Therapeutic use of methionine for the treatment or prevention of mucositis
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
KR20050099311A (ko) 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
WO2006037031A2 (en) * 2004-09-27 2006-04-06 Valentis, Inc. Formulations and methods for treatment of inflammatory diseases
MX2007009748A (es) 2005-02-14 2007-09-26 Univ Florida State Res Found Composiciones de taxano sustituidas con esteres ciclopropilicos en c10.
GB0517092D0 (en) 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
SG165404A1 (en) * 2005-09-26 2010-10-28 Hospira Australia Pty Ltd Fulvestrant formulation
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8338416B2 (en) 2006-03-16 2012-12-25 Pharmacylics, Inc. Indole derivatives as inhibitors of histone deacetylase
US20100098735A1 (en) 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
CN101677987A (zh) 2007-06-22 2010-03-24 赛多斯有限责任公司 不含吐温80的多西他赛的增溶制剂
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8586625B2 (en) 2008-01-16 2013-11-19 Anwar Rayan Derivatives of taxol and closely related compounds
JP2011514349A (ja) 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
EP2276755A4 (en) 2008-03-31 2011-05-04 Univ Florida State Res Found C (10) -ETHYESTER- AND C (10) -CYCLOPROPYLESTER-SUBSTITUTED TAXANES
KR20100018741A (ko) 2008-08-07 2010-02-18 신풍제약주식회사 도세탁셀 함유 항암용 주사제 조성물

Similar Documents

Publication Publication Date Title
WO2009111057A4 (en) Fulvestrant formulations
WO2011094565A1 (en) Formulations of bendamustine
WO2006052921A3 (en) Cyclodextrin solubilizers for liquid and semi-solid formulations
IL170297A (en) Intranasal formulation of rotigotine
EP1575585A1 (en) Pharmaceutical liquid composition containing pyridone derivative
RU2013104401A (ru) Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы
JP2019526532A5 (enExample)
JP2016516784A (ja) 分散安定化剤としてポリエチレングリコール系高分子及び／またはビニルピロリドン系高分子を含むタダラフィル遊離塩基含有フィルム剤形
WO2015178679A1 (ko) 안정성을 향상시킨 로티고틴 함유 경피흡수제제
WO2009120885A3 (en) Stabilizing lipid compositions for oral pharmaceutical agents
JP2010534703A (ja) トラゾドン系の安定な液状医薬組成物
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
JP2013525412A (ja) クルクミンを局所投与するための粘着性の遅効性配合物
JP2026016690A5 (enExample)
EP2836199B1 (en) Fulvestrant formulations
JP5624766B2 (ja) アルコールを含まないアルガトロバン製剤
TW200911302A (en) Pharmaceutical solutions
EP0949923A1 (fr) Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
WO2005074890A1 (en) Semisolid matrix pharmaceutical formulations
US8507468B2 (en) Intranasal anti-convulsive compositions and methods
WO2008062274A2 (en) Pharmaceutical formulations of nsaids for parentral use
JP7543365B2 (ja) ペメトレキセド製剤
JP2000515556A (ja) ニメスライド含有経口投与用薬剤
KR102794126B1 (ko) 페메트렉시드 제제
JP2007514778A5 (enExample)